Biodexa Pharmaceuticals Presents 12-Month Phase 2 Clinical Trial Results Of eRapa In Familial Adenomatous Polyposis To Be Presented At The Biennial InSIGHT 2024 Meeting
Portfolio Pulse from Benzinga Newsdesk
Biodexa Pharmaceuticals (NASDAQ: BDRX) will present 12-month Phase 2 clinical trial results of eRapa in Familial Adenomatous Polyposis at the InSIGHT 2024 meeting in Barcelona. The presentation will be given by Dr. Carol Burke, who previously presented six-month data at the Digestive Disease Weekly meeting.
June 10, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biodexa Pharmaceuticals will present 12-month Phase 2 clinical trial results of eRapa in Familial Adenomatous Polyposis at the InSIGHT 2024 meeting. This could generate positive investor sentiment and potential stock price movement.
The presentation of 12-month clinical trial results at a prestigious conference can generate significant investor interest and potentially drive the stock price up. The previous presentation of six-month data also adds credibility.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100